Wall Street Zen downgraded shares of Kalaris Therapeutics (NASDAQ:KLRS – Free Report) from a hold rating to a sell rating in a report published on Sunday morning,Wall Street Zen reports.
A number of other analysts also recently commented on KLRS. TD Cowen initiated coverage on shares of Kalaris Therapeutics in a report on Monday, June 15th. They issued a “buy” rating for the company. Weiss Ratings cut Kalaris Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Kalaris Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $18.75.
Kalaris Therapeutics Stock Performance
Kalaris Therapeutics (NASDAQ:KLRS – Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.02. As a group, sell-side analysts predict that Kalaris Therapeutics will post -1.99 EPS for the current fiscal year.
Institutional Investors Weigh In On Kalaris Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the company. Pale Fire Capital SE acquired a new position in Kalaris Therapeutics in the second quarter valued at about $161,000. Velan Capital Investment Management LP raised its stake in shares of Kalaris Therapeutics by 38.9% in the 2nd quarter. Velan Capital Investment Management LP now owns 25,000 shares of the company’s stock valued at $102,000 after acquiring an additional 7,000 shares during the period. Sigma Planning Corp purchased a new stake in shares of Kalaris Therapeutics in the 2nd quarter valued at approximately $41,000. Stonepine Capital Management LLC acquired a new position in shares of Kalaris Therapeutics in the 2nd quarter worth approximately $122,597. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Kalaris Therapeutics in the 2nd quarter worth approximately $407,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.
Kalaris Therapeutics Company Profile
Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.
Featured Stories
- Five stocks we like better than Kalaris Therapeutics
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
- MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
Receive News & Ratings for Kalaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
